
What Makes Argenx (ARGX) a New Buy Stock
Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
آخرین اخبار مالی و اقتصادی، تحولات بازار، گزارشها و تحلیلهای بازارهای مالی را در PipVero دنبال کنید.

Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does BJ's Restaurants (BJRI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zebra Technologies tops second-quarter earnings and revenue estimates as broad-based growth and acquisitions fuel sales, prompting higher full-year 2026 guidance.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

POWL's fiscal Q3 earnings and revenues miss estimates, even as record orders and a $2.4 billion backlog strengthen its outlook.

Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.

Flag Ship Acquisition NASDAQ: ETHZ executives, speaking during a Forum Markets presentation hosted by Force Family Office, outlined a strategy centered on acquiring cash-generating real-world assets while maintaining the option to fractionalize and tokenize those assets as the market develops.

Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.

Reservoir Media NASDAQ: RSVR opened fiscal 2027 with revenue growth across its music publishing and recorded music operations, while reaffirming its full-year financial outlook and highlighting new investments in Latin music, artist development and catalog acquisitions.

Freightcar America NASDAQ: RAIL reported second-quarter results marked by strong order intake and backlog growth, but lowered its 2026 delivery, revenue and adjusted EBITDA outlook after a planned production ramp began later than expected.

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.

People Incorporated Common Stock NASDAQ: PPLI reported continued digital revenue growth and higher profitability in its second quarter, while outlining plans to simplify its corporate structure, monetize non-core assets and invest in its core media operations and MGM holdings.

Powell Industries NASDAQ: POWL reported record third-quarter order bookings and a backlog that surpassed $2 billion for the first time in its 79-year history, as demand remained strong across data centers, electric utilities, LNG and other industrial markets.

Otter Tail NASDAQ: OTTR reported second-quarter adjusted diluted earnings per share of $1.66, down from $1.85 a year earlier, as lower PVC pipe pricing weighed on its plastics segment. The company raised its full-year adjusted earnings guidance to a range of $5.68 to $6.08 per share, excluding the after-tax effect of a legal settlement related to PVC pipe antitrust litigation.